Molecular Basis for the Selectivity of DHA and EPA in Sudlow's Drug Binding Sites in Human Serum Albumin with the Combined Use of NMR and Docking Calculations

Medium- and long-chain saturated and unsaturated free fatty acids (FFAs) are known to bind to human serum albumin (HSA), the main plasma carrier protein. Atomic-level structural data regarding the binding mode in Sudlow's sites I (FA7) and II (FA4, FA3) of the polyunsaturated ?-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), however, are largely unknown. Herein, we report the combined use of saturation transfer difference (STD) and Interligand NOEs for Pharmacophore Mapping (INPHARMA) NMR techniques and molecular docking calculations to investigate the binding mode of DHA and EPA in Sudlow's sites I and II of HSA. The docking calculations and the significant number of interligand NOEs between DHA and EPA and the drugs warfarin and ibuprofen, which are stereotypical ligands for Sudlow's sites I and II, respectively, were interpreted in terms of competitive binding modes and the presence of two orientations of DHA and EPA at the binding sites FA7 and FA4. The exceptional flexibility of the long-chain DHA and EPA and the formation of strongly folded structural motives are the key properties of HSA-PUFA complexes.

Automated summary

Medium- and long-chain saturated and unsaturated free fatty acids can bind to human serum albumin (HSA), but the binding mode of polyunsaturated ?-3 fatty acids DHA and EPA in Sudlow's sites I and II of HSA is largely unknown. This study used STD, INPHARMA NMR techniques, and molecular docking calculations to investigate the binding mode of DHA and EPA in Sudlow's sites I and II of HSA. The results showed competitive binding modes of DHA and EPA with stereotypical ligands for Sudlow's sites I and II, and two orientations of DHA and EPA at the binding sites FA7 and FA4.